86% of STOXX 600 constituents traded higher yesterday.
43% of the shares trade above their 20D MA vs 28% Friday (below the 20D moving average).
48% of the shares trade above their 200D MA vs 44% Friday (below the 20D moving average).
The Euro Stoxx 50 Volatility index eased 0.91pt to 25.76, a new 52w high.
SECTORS vs STOXX 600
3mths relative high: Financial Services, Industrial
3mths relative low: Telecom.
Europe Best 3 sectors
automobiles & parts, media, construction & materials
Europe worst 3 sectors
real estate, food & beverage, telecommunications
The 10yr Bund yield rose 2bps to -0.52% (below its 20D MA). The 2yr-10yr yield spread rose 1bp to -17bps (above its 20D MA).
FR 07:45: Jun Budget Balance, exp.: E-117.9B
EC 10:00: Jun PPI YoY, exp.: -5%
EC 10:00: Jun PPI MoM, exp.: -0.6%
In Asian trading hours, major currencies rebounded against the U.S. dollar. EUR/USD climbed higher nearing 1.1770, GBP/USD was at elevated levels around 1.3075. USD/JPY managed to stay above 106.00. AUD/USD advanced to levels above 0.7130. As expected, Australia's central bank kept its key interest rate unchanged at 0.25%. Official data showed that Australia's June Retail Sales grew 2.7% on month (+2.4% expected) and Exports increased 3% (+4% expected).
Spot gold was little changed at $1,973 an ounce.
#UK - IRELAND#
BP, oil major, announced 2Q results: "Underlying replacement cost loss for the quarter was 6.7 billion dollars, compared with a profit of 2.8 billion dollars for the same period a year earlier. The result was driven primarily by non-cash Upstream exploration write-offs - 6.5 billion dollars after tax (...) combined with the impact of lower oil and gas prices and very weak refining margins, reduced oil and gas production and much lower demand for fuels and lubricants. Oil trading delivered an exceptionally strong result. (...) A dividend of 5.25 cents per share was announced for the quarter, compared to 10.5 cents per share for the previous quarter."
Bayer, a German healthcare giant, said it swung to a 2Q net loss of 9.55 billion euros from a net income of 404 million euros in the prior-year period, citing net special charges of 12.51 billion euros. 2Q EBITDA before special items increased 5.6% on year to 2.88 billion euros on sales of 10.05 billion euros, up 2.5% on a currency- and portfolio-adjusted basis. The Company lowered its forecast on full-year EBITDA before special items to 12.1 billion euros from 12.3-12.6 billion euros previously and that on Core earnings per share to 6.70-6.90 euros from 7.00-7.20 euros.
Hugo Boss, a German premium-apparel company, announced that it swung to a 2Q net loss of 186 million euros from a net income of 52 million euros in the prior-year period on sales of 275 million euros, down 59% on year. The Company said: "Retail sales trends during the second quarter have shown a sequential improvement month by month. This positive trend has also continued so far in Q3, as HUGO BOSS has recorded further improvements in its global retail operations during the month of July."
Fraport, the operator of Frankfurt airport, posted a 1H net loss of 231 million euros, compared with a net income of 165 million euros in the prior-year period on revenue of 911 million euros, down 49% on year. The Company pointed out: "Frankfurt Airport's passenger traffic plummeted by 94.4% year-on-year in the April-to-June 2020 period, while falling by a total of 63.8% during the entire first half."
Infineon Technologies, a semiconductors maker, reported that it swung to a 3Q net loss of 128 million euros from a net income of 224 million euros in the prior-year period.
DSM, a Dutch nutrition and health company, reported that 1H net income fell to 270 million euros from 401 million euros in the prior-year period. 1H Adjusted EBITDA eased 4.3% on year to 825 million euros on sales of 4.53 billion euros, slightly lower than 4.57 billion euros a year earlier.
Novartis, a Swiss maker of pharmaceutical products, reported positive results from a Phase 2 trial of Kymriah (tisagenlecleucel) in patients with relapsed or refractory follicular lymphoma.
FLSmidth & Co, a machinery firm, reported that 2Q EBITA decreased 73% on year to 131 million Danish Krone on revenue of 3.85 billion Danish Krone, down 30%. The Company said: "The clear majority of the revenue decline was attributable to COVID-19, but the change was also a result of a lower backlog entering the year."
From a weekly point of view, the stock remains within a bearish channel since June 2018. Below 214.7 krone, targets are set at 170 Krone and 134.30 krone in extension.
Source: GAIN Capital, TradingView
Disclaimer: GAIN Capital UK Limited (trading as "Forex.com") is an execution-only service provider. This material, whether or not it states any opinions, is for general information purposes only and it does not take into account your personal circumstances or objectives. This material has been prepared using the thoughts and opinions of the author and these may change. However, Forex.com does not plan to provide further updates to any material once published and it is not under any obligation to keep this material up to date. This material is short term in nature and may only relate to facts and circumstances existing at a specific time or day. Nothing in this material is (or should be considered to be) financial, investment, legal, tax or other advice and no reliance should be placed on it.
No opinion given in this material constitutes a recommendation by Forex.com or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person. The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although Forex.com is not specifically prevented from dealing before providing this material, Forex.com does not seek to take advantage of the material prior to its dissemination. This material is not intended for distribution to, or use by, any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation.
For further details see our full non-independent research disclaimer and quarterly summary.